The Company wishes to remind its shareholders and the market generally that a series of mid-year briefings will be held.
Noxopharm CEO , Dr Graham Kelly and the Director of Clinical Development and Medical Affairs, Ian Minns will present updates on the Company’s clinical programme.
In addition, the Nyrada Chief Scientific Officer, James Bonnar and Chair of the Nyrada Scientific Advisory Board, Professor Gary Housley of the University of New South Wales, Sydney, will provide updates on that Company’s scientific progress at the briefings in Sydney and Melbourne.
For further information please download PDF attached:
Download this document
